

In the Claims:

Claims 1 to 22 (cancelled).

Claim 23. (presently amended) A lipopeptide comprising at least one auxiliary T epitope, at least one CTL epitope and one lipid moiety wherein the lipid moiety consists of a unbranched or branched, unsaturated or saturated, chain derived from fatty acids of 10 to 20 carbon atoms:

the at least one CTL epitope consists of a CTL epitope of a HIV protein;
and wherein

the lipid moiety and the epitopes are separated by hydrophilic aminoacid spacer chain having a length of 1 to 10 aminoacids, said aminoacids residues being independently selected from glycine, arginine, glutamic acid, asparatic acid and cysteine;
or

two distinct epitopes are separated by a hydrophilic aminoacid spacer chain having a length of 1 to 10 aminoacids, said aminoacids residues being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine; or

both the lipid moiety and the epitopes on the one hand, and the epitopes, on the other hand, are separated by an aminoacid spacer chain selected from the group consisting of GLY ARG and ARG GLY ARG, having a length of 1 to 10 aminoacids, said aminoacids being independently selected from glycine, arginine, glutamic acid, aspartic acid and cysteine

Claim 24 to 27(cancelled)

Claim 28 (previously presented) A lipopeptide of claim 23 wherein the amino acid spacer chain comprises an alkyl functionalized by a thiol and non-peptide bonds.

Claim 29 (previously presented) A lipopeptide of claim 23 wherein the amino acid spacer chain comprises a member selected from the group consisting of thiazolidine, oxime and hydrazone.

Claim 30 (previously presented) A lipopeptide of claim 23 comprised of a lipid – a first spacer – an auxiliary T eopitope – a second spacer – a CTL epitope.

Claim 31 (previously presented) A lipopeptide of claim 23 comprised of a lipid – a first spacer – auxiliary T epitope – a second spacer – a first CTL epitope – a second CTL epitope.

Claims 32 - 34 (cancelled)

Claim 35 (previously presented) A lipopeptide of claim 23 wherein the lipid is a moiety selected from the group consisting of palmitic acid, oleic acid, linoleic acid, 2-amino hexadecanoic acid, pimelautide and trimexautide.

Claim 36 (previously presented) A lipopeptide of claim 23 wherein the non-lipid portion is comprised of 15 to 100 amino acids.

Claim 37 (previously presented) A lipopeptide of claim 23 wherein the auxiliary T epitope is a multivalent epitope.

Claim 38 (presently amended) A lipopeptide of claim 23 wherein the auxiliary T epitope is the 830-843 peptide of ~~titanie~~ tetanus toxin with the sequence QYIKANSKFIGITE.

Claim 39 (previously presented) A lipopeptide of claim 23 wherein the auxiliary T epitope is haemagglutinin epitope or PADRE epitope.

Claim 40 (cancelled).

Claim 41 (previously presented) A method of inducing a specific immune response against HIV in a warm-blooded animal comprising administering to a warm-blooded animal an amount of a lipopeptide of claim 23 sufficient to induce a specific immune response.

Claim 42 (cancelled).

Claim 43 (previously presented) A vaccine comprising an immune inducing effective amount of at least one lipopeptide of claim 23.